Patient details and summary of results
. | . | V617F-positive . | . | . | V617F-negative . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease subtype . | No. patients . | No. patients (%) . | No. male/no. female . | Median age, y (range) . | No. patients (%) . | No. male/no. female . | Median age, y (range) . | V617F homozygotes no. (% of mutants) . | ||||
| PV | 72* | 58 (81) | 31/27 | 57 (26-76) | 14 (19) | 13/1 | 57 (33-78) | 24 (41) | ||||
| ET | 59 | 24 (41) | 15/9 | 65 (5-88) | 35 (59) | 23/12 | 56 (24-88) | 4 (17) | ||||
| IMF | 35 | 15 (43) | 10/5 | 65 (44-78) | 20 (57) | 15/5 | 62 (41-92) | 10 (67) | ||||
| Idiopathic HES | 134† | 2 (1.5) | 1/1 | 64 (63-65) | 132 (99) | 51/81 | 54 (3-89) | 2 (100) | ||||
| Mastocytosis | 28‡ | 0 (0) | NA | NA | 28 (100) | 16/12 | 53 (4-90) | NA | ||||
| CML-like MPDs | 99§ | 17 (17) | 13/4 | 62 (17-76) | 82 (83) | 60/22 | 66 (2-95) | 8 (47) | ||||
| Unclassified MPD | 53 | 13 (25) | 7/6 | 63 (17-77) | 40 (75) | 17/23 | 61 (21-87) | 7 (54) | ||||
| Total | 480 | 129 (27) | 77/52 | 58 (2-95) | 351 (73) | 195/156 | 62 (5-88) | 55 (43) | ||||
. | . | V617F-positive . | . | . | V617F-negative . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease subtype . | No. patients . | No. patients (%) . | No. male/no. female . | Median age, y (range) . | No. patients (%) . | No. male/no. female . | Median age, y (range) . | V617F homozygotes no. (% of mutants) . | ||||
| PV | 72* | 58 (81) | 31/27 | 57 (26-76) | 14 (19) | 13/1 | 57 (33-78) | 24 (41) | ||||
| ET | 59 | 24 (41) | 15/9 | 65 (5-88) | 35 (59) | 23/12 | 56 (24-88) | 4 (17) | ||||
| IMF | 35 | 15 (43) | 10/5 | 65 (44-78) | 20 (57) | 15/5 | 62 (41-92) | 10 (67) | ||||
| Idiopathic HES | 134† | 2 (1.5) | 1/1 | 64 (63-65) | 132 (99) | 51/81 | 54 (3-89) | 2 (100) | ||||
| Mastocytosis | 28‡ | 0 (0) | NA | NA | 28 (100) | 16/12 | 53 (4-90) | NA | ||||
| CML-like MPDs | 99§ | 17 (17) | 13/4 | 62 (17-76) | 82 (83) | 60/22 | 66 (2-95) | 8 (47) | ||||
| Unclassified MPD | 53 | 13 (25) | 7/6 | 63 (17-77) | 40 (75) | 17/23 | 61 (21-87) | 7 (54) | ||||
| Total | 480 | 129 (27) | 77/52 | 58 (2-95) | 351 (73) | 195/156 | 62 (5-88) | 55 (43) | ||||
NA indicates not applicable.
Includes one case with PV plus systemic mastocytosis who was positive for V617F and KIT D816V.
Includes 7 FIP1L1-PDGFRA-positive CEL cases, all of whom were negative for V617F.
Includes 7 KITD816V-positive cases, all of whom were negative for V617F.
Includes 17 cases with rare tyrosine kinase fusions (ETV6-PDGFRB, n = 9; ZNF198-FGFR1, n = 2; BCR-FGFR1, n = 2; PCM1-JAK2, n = 2; BCR-PDGFRA, n = 1; TP53BP1-PDGFRB, n = 1), all of whom were negative for V617F.